We found that upregulation of p38β, but not p38α, is a common event in AML cases that contributes to the SET-dependent inactivation of PP2A in AML, pointing to a relevant role of p38β in this aggressive disease. The gene discussed is PTPA; the disease is acute myeloid leukemia.